Bogle Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bogle Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-9,901	Closed	-$2.87M	–	327
2020 Q2	$2.87M	Buy	+9,901	New	+$2.68M	0.48%	98
2018 Q4	–	Sell	-75,733	Closed	-$14.6M	–	426
2018 Q3	$14.6M	Buy	+75,733	New	+$13.5M	1.05%	30
2018 Q2	–	Sell	-71,069	Closed	-$11.6M	–	354
2018 Q1	$11.6M	Sell	71,069 -11,723	-14%	-$1.91M	0.87%	49
2017 Q4	$12.4M	Sell	82,792 -12,509	-13%	-$1.85M	0.91%	39
2017 Q3	$14.5M	Hold	95,301	–	–	0.99%	19
2017 Q2	$12.3M	Buy	+95,301	New	+$11.5M	0.9%	30

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bogle Investment Management's VRTX Position: Q3 2020 in Review

Bogle Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 9,901 shares — an estimated $2.87M sold.

Bogle Investment Management first reported a position in VRTX in Q2 2017 and held it in 6 quarters. The position peaked at $14.6M in Q3 2018. 950 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

Bogle Investment Management reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bogle Investment Management sold 9,901 Vertex Pharmaceuticals shares in Q3 2020, an estimated $2.87M.
Bogle Investment Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Bogle Investment Management's Vertex Pharmaceuticals position peaked at $14.6M in Q3 2018.
950 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.